A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefi t cardiovascular parameters, such as lipids, blood pressure, infl ammatory biomarkers, endothelial function and fi brinolytic state. In this review, we summarise thedoi:10.2147/vhrm.s993 fatcat:z2nty4akcbep5gqvb3762cg7py